This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           September 03, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store


Should ovaries be removed at the time of hysterectomy?
Medscape (Free login required)
A study published in June 2014 issue of Obstetrics Gynecology found that that both hysterectomy alone and hysterectomy with bilateral salpingo-oophorectomy (BSO) are associated with a reduction in cancer risk, especially when performed before 45 years of age. The risk for breast cancer is reduced by both surgical procedures when performed before age 45 years. Hysterectomy with BSO significantly reduces the risk for ovarian cancer.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Promising results from trial for late-stage peritoneal cancers
Oncology Nurse Advisor
A repurposed drug originally used to treat ovarian cancer produced positive results in patients with advanced peritoneal cancers during a phase I clinical trial, according to news releases issued last week by the University of Kansas Medical Center and the drug’s developer, CritiTech. The drug, known under the brand name Nanotax, is a fine particle reformulation of paclitaxel, the standard treatment for ovarian cancer. The drug was developed by CritiTech, based in Lawrence, Kansas; the drug testing and phase I clinical trial were conducted by researchers at The University of Kansas Cancer Center, in Lawrence, and led by Stephen Williamson, MD, medical director of Cancer Clinical Trials.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Experts say annual Pap tests can cause harm, Part 1: Yearly testing may not be right for you
The Bulletin
For years doctors have urged women to come in for annual Pap smear testing to screen for cervical cancer. But over the past decade, women’s health experts have recognized that such frequent testing not only doesn’t provide greater protection from cancer, it may be causing serious medical harm. Guidelines from groups including the American Cancer Society, the U.S. Preventive Health Services Task Force and the American College of Obstetricians and Gynecologists recommend less frequent testing for women at low risk for cervical cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.

Annual Pap test more risk than prevention for some, Part II: Financial issues may slow change to new Pap smear recommendations
The Bulletin
With the realization that a Pap test every year may expose women to greater harm than benefit, guidelines have shifted toward less frequent screening. But with so many women still being tested annually, experts are wondering whether physician reluctance to adopt the new screening schedule may be fueled by legitimate concerns about women’s health or by financial concerns. Pap testing is not a particularly lucrative procedure. Medicare pays physicians about $46 to collect the sample, Medicaid an average of $28.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Cancer patients often struggle with depression without getting any professional help
Tech Times
Cancer patients do not just battle with their physical ailment. Many also suffer from clinical depression. Unfortunately, as many as three-quarters of these patients to do not receive effective treatment for their condition, researchers from Oxford and Edinburgh universities in the U.K. have found. For their new study published in The Lancet Psychiatry on Aug. 28, Jane Walker, from the University of Oxford Department of Psychiatry at the Warneford Hospital in the U.K., and colleagues studied the data of more than 21,000 cancer patients in Scotland. They found that depression appears to be more common in patients with lung cancer, affecting about 13 percent of lung cancer patients involved in the study, followed by those diagnosed with gynecological cancer (10.9 percent).
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Work for the best
We are seeking a gyn-oncologist to join our growing health system in Springfield, Mo. Our clinic has on-site lab and radiology services, access to a da Vinci® surgical robot and a strong support staff. For more information about this opportunity at our physician owned and operated clinic, call 1-800-869-4201. MORE
Exceptional Care, Close to Home

21st Century Oncology – the nation’s largest cancer treatment network and global leader in cancer care – providing integrated clinical teams treating patients collaboratively to improve outcomes.


Preventing cancer from forming 'tentacles' stops dangerous spread
Science Daily
A new study from the research group of Dr. John Lewis at the University of Alberta and the Lawson Health Research Institute has confirmed that "invadopodia" play a key role in the spread of cancer. The study, published in Cell Reports, shows preventing these tentacle-like structures from forming can stop the spread of cancer entirely. Roughly 2 in 5 Canadians will develop cancer in their lifetime, and one in four of them will die of the disease. In 2014, it's estimated that nine Canadians will die of cancer every hour.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Biomarker for aggressive, basal-like breast cancer identified
Oncology Nurse Advisor
A biomarker strongly associated with basal-like breast cancer has been identified. Basal-like breast cancer is a highly aggressive carcinoma that is resistant to many types of chemotherapy. The biomarker, STAT3 protein, provides a smart target for new therapeutics designed to treat this often deadly cancer. Using breast cancer patient data taken from The Cancer Genome Atlas, molecular biologists Curt M. Horvath, PhD, and Robert W. Tell, PhD, both of Northwestern University in Evanston, Illinois, used powerful computational and bioinformatics techniques to detect patterns of gene expression in two cancer subtypes. They found that a small number of genes are activated by STAT3 protein signaling in basal-like breast cancers but not in luminal breast cancers.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news

Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Aug. 27, 2014
Aug. 20, 2014
Aug. 13, 2014
July 30, 2014

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063